SITC Awards $150,000 in Fellowships to Fuel Cancer Immunotherapy Research in 2026
The Society for Immunotherapy of Cancer (SITC) aims to make significant strides in cancer treatment through its dedicated Forward Fund. Recently, they announced the recipients of the SITC Fellowships for 2026, allocating an impressive $150,000 to nurture early-career researchers whose innovative scientific inquiries are poised to advance immunotherapy and foster better outcomes for cancer patients.
Dr. Sandra Demaria, Vice President of SITC, emphasized the critical importance of visionary researchers during a recent announcement. She stated, "Every advance in cancer immunotherapy begins with researchers willing to ask bold questions and pursue new possibilities." With the Forward Fund, SITC is not merely tokenistically funding researchers; they are investing in the scientific minds that will forge the future of immunotherapy.
The commitment to funding is aimed at building a solid foundation that will lead to groundbreaking treatments. Since its inception in 2014, the Forward Fund has successfully disbursed over $6 million in fellowships, enabling ambitious scientists to tackle some of the most daunting challenges in the immunotherapy landscape.
At the upcoming SITC Annual Meeting, set to occur from November 4 to 8 at the Phoenix Convention Center, the 2026 fellowship recipients will receive well-deserved recognition for their pioneering work.
This year's fellowship recipients include:
These selected researchers exemplify the kind of innovative thinking that the Forward Fund seeks to promote, focusing on the urgency of delivering new therapeutic options to patients facing cancer.
The SITC is actively inviting applications for the upcoming 2027-2028 NCI Immunotherapy Fellowship, continuing its mission to cultivate young talent in the field of immunotherapy. More details about previous and current fellowship recipients can be found on the SITC website.
Founded in 1984, the Society for Immunotherapy of Cancer has grown into a global leader in advancing the science of cancer treatment. It unites influential figures from various sectors, including scientific, healthcare, government, and industry, all working toward one ambitious goal: to make the word "cure" a reality for patients suffering from cancer.
Through its array of programs and initiatives, including educational offerings that facilitate collaboration and scientific exchange among experts, SITC is at the forefront of fostering innovative solutions in cancer care. To stay updated on their initiatives and advancements in immunotherapy, follow SITC on social media platforms such as X, LinkedIn, Facebook, Instagram, and YouTube.
A Commitment to the Future of Cancer Research
Dr. Sandra Demaria, Vice President of SITC, emphasized the critical importance of visionary researchers during a recent announcement. She stated, "Every advance in cancer immunotherapy begins with researchers willing to ask bold questions and pursue new possibilities." With the Forward Fund, SITC is not merely tokenistically funding researchers; they are investing in the scientific minds that will forge the future of immunotherapy.
The commitment to funding is aimed at building a solid foundation that will lead to groundbreaking treatments. Since its inception in 2014, the Forward Fund has successfully disbursed over $6 million in fellowships, enabling ambitious scientists to tackle some of the most daunting challenges in the immunotherapy landscape.
Recognizing Talent and Innovation
At the upcoming SITC Annual Meeting, set to occur from November 4 to 8 at the Phoenix Convention Center, the 2026 fellowship recipients will receive well-deserved recognition for their pioneering work.
This year's fellowship recipients include:
- - SITC-Merck Cancer Immunotherapy Clinical Fellowship awarded to Dr. Janna Minehart from the University of Pennsylvania. Dr. Minehart’s project focuses on enhancing CAR T cell function through a reversible TET2 "off switch," providing a new angle on one of the most advanced therapies in cancer treatment.
- - SITC Cancer Immunotherapy Fellowship, given to Dr. Simon Milette from Yale University. His research targets PRMT5 as a novel approach to unlock T cell cytotoxicity in melanoma, shedding light on potential new methodologies in treating this aggressive form of skin cancer.
- - NCI Immunotherapy Fellowship, awarded to Dr. Nicholas C. Love from the University of Rochester Medical Center, who has accepted a year-long position that will immerse him in research at the esteemed National Cancer Institute.
These selected researchers exemplify the kind of innovative thinking that the Forward Fund seeks to promote, focusing on the urgency of delivering new therapeutic options to patients facing cancer.
The Road Ahead
The SITC is actively inviting applications for the upcoming 2027-2028 NCI Immunotherapy Fellowship, continuing its mission to cultivate young talent in the field of immunotherapy. More details about previous and current fellowship recipients can be found on the SITC website.
Founded in 1984, the Society for Immunotherapy of Cancer has grown into a global leader in advancing the science of cancer treatment. It unites influential figures from various sectors, including scientific, healthcare, government, and industry, all working toward one ambitious goal: to make the word "cure" a reality for patients suffering from cancer.
Through its array of programs and initiatives, including educational offerings that facilitate collaboration and scientific exchange among experts, SITC is at the forefront of fostering innovative solutions in cancer care. To stay updated on their initiatives and advancements in immunotherapy, follow SITC on social media platforms such as X, LinkedIn, Facebook, Instagram, and YouTube.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.